Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Sep;54(6):846-847.
doi: 10.1111/apt.16555.

Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence

John P Haydek  1 , Frank I Scott  1
Affiliations
Editorial

Editorial: infliximab or adalimumab as first- or second-line anti-TNF-conflicting evidence

John P Haydek et al. Aliment Pharmacol Ther. 2021 Sep.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381:1215-1226.
    1. Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201-1214.
    1. Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018;48:394-409.
    1. Meserve J, Barsky M, Dulai PS. In the absence of head-to-head trials, what do real world studies tell us about the comparative effectiveness of biologics in Crohn's disease. Best Pract Res Clin Gastroenterol. 2019;38-39: 101619.
    1. Singh S. Network meta-analysis to inform positioning of biologics in patients with Crohn's disease: promise and perils. Best Pract Res Clin Gastroenterol. 2019;38-39:101614.

LinkOut - more resources